cagrilintide novo Nordisk flags promise in hunt for next obesity drug Topline data from REDEFINE 1
Topline data from REDEFINE 1 found CagriSema, a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg, achieved superior weight loss versus placebo in adults with obesity or overweight. https: t.co JA9E3FpCsN #ObesityManagement # Cagrilintide Peptide 99% Pure Nationwide Peptides Novo's CagriSema Outshines Semaglutide In Phase III Diabetes Study Novo Nordisk's stock drops despite CagriSema hitting goal of Phase III trial Clinical Trials Arena Weight loss: New drug CagriSema leads to 14% weight loss in trial
Pay in 4 interest-free payments of $6.05 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21



